Atracurium and vecuronium: two unique neuromuscular blocking agents

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Nondepolarizing skeletal muscle relaxants are crucial in anesthesia.
• Existing agents like tubocurarine have limitations, including dependence on renal and hepatic function for elimination and potential cardiovascular side effects.

Purpose of the Study:

• To introduce and compare two new nondepolarizing muscle relaxants: atracurium and vecuronium.
• To highlight their unique metabolic profiles and clinical advantages over older agents.

Main Methods:

• Comparative analysis of atracurium and vecuronium.
• Evaluation of their metabolic pathways, duration of action, cumulative effects, cardiovascular impact, and histamine release.
• Assessment of safety in patients with renal and hepatic dysfunction.

Main Results:

• Both atracurium and vecuronium offer shorter durations of action and minimal cumulative effects compared to older relaxants.
• Neither agent requires normal renal function for excretion, making them suitable for patients with renal failure.
• Atracurium is independent of hepatic metabolism, while vecuronium may need dose adjustments in hepatic disease.
• Both exhibit fewer cardiovascular effects and less histamine release than older agents, though atracurium may cause more histamine-like reactions.

Conclusions:

• Atracurium and vecuronium represent advancements in nondepolarizing muscle relaxants.
• Their unique properties offer improved safety profiles, particularly in patients with renal or hepatic impairment.
• Vecuronium is recommended for patients with asthma or allergies due to lower histamine release.